Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101468102 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1755-3768 (Electronic) Linking ISSN: 1755375X NLM ISO Abbreviation: Acta Ophthalmol Subsets: MEDLINE
    • بيانات النشر:
      Publication: Oxford, UK : Wiley-Blackwell
      Original Publication: Oxford, UK ; Malden, MA : Blackwell Munksgaard
    • الموضوع:
      Photochemotherapy*; Angiogenesis Inhibitors/*therapeutic use ; Choroidal Neovascularization/*drug therapy ; Polyps/*drug therapy ; Ranibizumab/*therapeutic use ; Visual Acuity/*physiology; Aged ; Aged, 80 and over ; Choroidal Neovascularization/diagnostic imaging ; Choroidal Neovascularization/physiopathology ; Coloring Agents/administration & dosage ; Combined Modality Therapy ; Female ; Fluorescein Angiography ; Humans ; Indocyanine Green/administration & dosage ; Intravitreal Injections ; Male ; Middle Aged ; Polyps/diagnostic imaging ; Polyps/physiopathology ; Retrospective Studies ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
    • نبذة مختصرة :
      Purpose: To compare 3-year visual outcomes after intravitreal ranibizumab (IVR) monotherapy and combination therapy of photodynamic therapy (PDT) with IVR for polypoidal choroidal vasculopathy (PCV).
      Methods: Medical records for 45 eyes in 45 patients (34 men, 11 women; mean age, 73.8 years old; range, 62-86 years old) with treatment-naïve PCV were reviewed retrospectively. Of the 45 eyes, 20 were treated with IVR monotherapy and 25 with combination therapy. Mean change in best-corrected visual acuity, numbers of injections of IVR and length of treatment-free period from baseline at month 36 were observed. Adverse events were monitored.
      Results: The change in visual acuity after combination therapy was significantly better than that after IVR monotherapy (p = 0.0399). At 36 months, improvement in visual acuity was seen in five eyes (25.0%) in the IVR monotherapy group and 13 eyes (52.0%) in the combination therapy group. The treatment-free period was significantly longer in the combination therapy group (p = 0.0008). Additional IVR therapy was required significantly more frequently in the IVR monotherapy group (p = 0.0026). Post-treatment subretinal haemorrhage or retinal pigment epithelium tear occurred only in the IVR monotherapy group, in one eye (5.0%) and one eye (5.0%), respectively.
      Conclusion: Initial therapy consisting of a single session of PDT combined with IVR improves vision in treatment-naïve PCV. Compared with IVR monotherapy, this combination therapy may be more effective for PCV.
      (© 2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
    • Comments:
      Comment in: Acta Ophthalmol. 2018 Mar;96(2):e254-e255. (PMID: 28456139)
    • Contributed Indexing:
      Keywords: VEGF; photodynamic therapy; polypoidal choroidal vasculopathy; ranibizumab
    • الرقم المعرف:
      0 (Angiogenesis Inhibitors)
      0 (Coloring Agents)
      0 (VEGFA protein, human)
      0 (Vascular Endothelial Growth Factor A)
      IX6J1063HV (Indocyanine Green)
      ZL1R02VT79 (Ranibizumab)
    • الموضوع:
      Date Created: 20160531 Date Completed: 20170126 Latest Revision: 20220311
    • الموضوع:
      20231215
    • الرقم المعرف:
      10.1111/aos.13130
    • الرقم المعرف:
      27237048